Therapeutic potential of ETA selective antagonist in OA.

ETA 选择性拮抗剂在 OA 中的治疗潜力。

• 批准号: 176421
• 负责人: Moldovan Florina F
• 金额: $ 6.9万
• 依托单位: Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2009-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=176421&lang=en
• 关键词: Cell Signalling; Endothelins; Human Cartilage Tissues; Matrix Degradation

Osteoarthritis (OA) is characterised by progressive joint destruction, inflammation and pain. There are no specific ways to stop OA and, because of its nature, only treatments begun during the early stages of the disease can assure those who live with it

骨关节炎（OA）的特征在于进行性关节破坏、炎症和疼痛。没有特定的方法来阻止OA，并且由于其性质，只有在疾病的早期阶段开始的治疗才能确保那些患有OA的人